CoChat

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background: Topical tretinoin’s role in acne has been established through evidence-based guidelines. Cutaneous irritation and potential to cause or exacerbate postinflammatory hyperpigmentation (PIH) may limit use.Objective: Evaluate safety and tolerability of novel polymeric formulation of tretinoin 0.05% lotion in moderate-to-severe acne.Methods: One thousand six hundred and forty patients randomized to tretinoin 0.05% lotion or vehicle in two double-blind placebo-controlled 12-week studies. Investigator-evaluated cutaneous safety (erythema and scaling) and patient-reported tolerability (itching, burning/stinging) assessed using a scale of 0 (none) to 3 (severe). Hyper- and hypo-pigmentation evaluated at each study visit. A number of subpopulations were investigated.Results: Tretinoin 0.05% lotion was considered safe and very well tolerated. Only application site pain (3.1%), dryness (3.7%) and erythema (1.4%) were reported by >1% or patients. Treatment-related adverse events were particularly rare (≤2%) in Hispanic and male subpopulations, and lower in adult females. The severity of cutaneous safety and tolerability scores remained <0.5 (where 1 = mild) and were generally lower than baseline severity. Tretinoin 0.05% lotion did not appear to cause or exacerbate PIH.Conclusions: A novel polymeric formulation of tretinoin 0.05% lotion provides a highly favorable safety and tolerability profile, with an incidence of erythema, dryness, and skin burning lower than that previously reported with other formulations of tretinoin.

Overview

Integrity signals

Registry

Crossref · 10.1080/09546634.2019.1587884

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 10

  1. Tanghetti E, 2010, J Drugs Dermatol, 9, 549
  2. Dosik JS, 2007, J Drugs Dermatol, 6, 632
  3. Leyden J, 2009, J Drugs Dermatol, 8, 383
  4. Tyring SK, 2018, J Drugs Dermatol, 17, 602
  5. Webster G, 2009, Cutis, 83, 146
  6. Nighland M, 2008, J Drugs Dermatol, 7, s2
  7. Draelos ZD, 2017, J Drugs Dermatol, 16, 591
  8. Tanghetti EA, 2018, J Drugs Dermatol, 17, 1192
  9. Taylor SC, 2018, J Drugs Dermatol, 17, 160
  10. Kircik L, J Drugs Dermatol

Cited by

See all 16

Metadata

Authors
Harper, J. C., Roberts, W. E., Zeichner, J. A., Guenin, E., Bhatt, V., & Pillai, R.
Affiliations
  • The Dermatology and Skin Care Center of Birmingham, Birmingham, AL, USA;
  • Generational and Cosmetic Dermatology, Mirage, CA, USA;
  • Mount Sinai Hospital (US)
  • Ortho Dermatologics, Bridgewater, NJ, USA;
  • Bausch Health (United States) (US)
Corresponding author
Harper, Julie C
Venue
Journal of Dermatological Treatment
Published
2019-04-02
Volume
31
Issue
2
Pages
160-167
ISSN
  • 0954-6634 (ISSN-L)
  • 1471-1753
OpenAlex
W2931024703
Cited by
16
References
22
Citations by year
2024: 3 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 4
FWCI
2.77
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Dermatological Treatment (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
Keywords
all-trans retinoic acid, acne, topical retinoids, once-daily treatment, skin irritation, post-inflammatory hyperpigmentation, skin tolerability, erythema, dryness, subpopulation differences, Hispanic patients, sex differences
MeSH terms
Acne Vulgaris, Adolescent, Adult, Child, Double-Blind Method, Drug Administration Schedule, Drug Tolerance, Female, Humans, Keratolytic Agents, Male, Middle Aged, Pain, Pruritus, Severity of Illness Index, Tretinoin, Placebo Effect, Treatment Outcome, Hyperpigmentation, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups. https://app.cochat.ai/papers/10.1080/09546634.2019.1587884
The paper
Harper, J. C., Roberts, W. E., Zeichner, J. A., Guenin, E., Bhatt, V., & Pillai, R. (2020). Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of safety and tolerability in subgroups. Journal of Dermatological Treatment. https://doi.org/10.1080/09546634.2019.1587884

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.